Safety and Immunogenicity Testing of a Pilot Polysaccharide Vaccine Preparation to Pseudomonas aeruginosa.
Abstract
We initiated studies on the development and testing of a high molecular weight polysaccharide vaccine to prevent burn and wound infections caused by Pseudomonas aeruginosa. These infections are serious complications of burn and wound injuries received by soldiers in combat. We have further purified high molecular weight polysaccharide from immunotype 1 and 2 strains of Pseudomonas aerguginosa and prepared and tested these materials in phase 1 safety and immunogenicity trials in healthy volunteers. We have also prepared for testing and phase 1 trials high molecular weight polysaccharide vaccines from the immunotype 3 and immunotype 4 strains. The immunotype 1 and immunotype 2 polysaccharide vaccines were very well tolerated by volunteers, showing no local or systemic reactions. Both vaccines elicited in the majority of volunteers an increase in binding and opsonic antibody two weeks longer following immunization. The immunotype 1 and 2 polysaccharide vaccines, along with immunotype 3 vaccine, were efficacious in preventing P. aeruginosa burn wound infections in a murine model. We conclude that P. aeruginosa high molecular weight polysaccharides offer significant potential as vaccines to prevent disease caused by this organism. We recommend strongly that further research and development be conducted in this field in order to provide the armed forces with a safe and reliable vaccine against P. aeruginosa infections.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 1983
- Accession Number
- ADA155424
Entities
People
- G. B. Pier
Organizations
- Brigham and Women's Hospital